The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of BCL-2 alternative proteins and outcome in patients with peripheral T-cell lymphoma (PTCL).
 
Mario L. Marques-Piubelli
No Relationships to Disclose
 
Luisa Maren Solis
No Relationships to Disclose
 
Luis Malpica
No Relationships to Disclose
 
Sushant Gouni
No Relationships to Disclose
 
Ranjit Nair
No Relationships to Disclose
 
Dai Chihara
No Relationships to Disclose
 
Swaminathan Padmanabhan Iyer
Honoraria - Seagen
Consulting or Advisory Role - Daiichi Sankyo; Legend Biotech; Seagen
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Novartis (Inst); Rhizen Pharmaceuticals (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Takeda
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bayer; Bristol-Myers Squibb; Flame Biosciences; Flame Biosciences; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Merck; MSD Oncology; OncoCyte; Pfizer
Speakers' Bureau - AstraZeneca; Merck; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
 
Francisco Vega
No Relationships to Disclose
 
Paolo Strati
Consulting or Advisory Role - Genentech/Roche
Research Funding - AstraZeneca